09/06/2026
𝐅𝐫𝐨𝐦 𝐂𝐨𝐦𝐩𝐥𝐞𝐱 𝐃𝐚𝐭𝐚 𝐭𝐨 𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥: A biotech developing a treatment for Geographic Atrophy needed to present consistent, regulator-ready evidence across multiple trials with different designs.
They needed more than good data.
They needed clear, regulator-ready insights across the entire program.
led the Integrated Summary of Safety (ISS) and Effectiveness (ISE), aligning datasets and applying a focused pooling strategy to support program-level conclusions—without delaying timelines.
𝐓𝐡𝐞 𝐨𝐮𝐭𝐜𝐨𝐦𝐞?
✔ FDA approval
✔ EMA MAA accepted two weeks later
When data complexity increases, the right statistical strategy becomes critical.
👉 Read the case study: https://go.iddi.com/l/1100512/2026-05-27/35x41z?utm_source=linkedin&utm_medium=organic_social&utm_campaign=ophthalmology_LinkedIn&utm_content=linkedin_post_4
👉 Or get in touch to discuss your next submission: https://iddi.com/contact/